Iatrogenic opioid addiction

Iatrogenic opioid addiction is opioid dependence arising from medical treatment, particularly when drugs prescribed for pain create or sustain dependence. The book presents it not as an isolated clinical mistake but as a recurring historical pattern: accepted prescribing expands access to opioids, dependence follows, and the resulting harm is often obscured by the assumption that addiction belongs to illicit users rather than to patients treated by doctors.

A medical origin, then a changed public image

In the 1870s, morphine injection was common among affluent users in Europe and the United States, prescribed for complaints ranging from menstrual pain to eye inflammation. With little regulatory oversight, morphine and opium remedies were available over the counter; a doctor’s initial approval could make even repeated injections socially acceptable. Because dependence followed medical treatment, daily users were not generally stigmatized as morally suspect. The origin of the drug use shaped how the user was seen.

That acceptance did not mean the dangers were invisible. In 1895, a Brooklyn doctor warned colleagues that leaving morphine and syringes with patients for use whenever pain arose was nearly criminal, noting that some patients became dependent after only three or four doses. By 1900, more than 250,000 Americans were addicted to opium-derived painkillers. The warning pointed to a central feature of iatrogenic addiction: the treatment intended to relieve pain could itself begin a dependence that patients might later struggle to escape.

The Harrison Narcotics Act and the national crackdown that followed helped contain the earlier wave of medically connected opium and morphine addiction. By the mid-twentieth century, opioids were largely associated in public understanding with cancer treatment or with illicit heroin use in major cities. The small-town patient whose dependence began with a prescription receded from view; the dominant image shifted toward the hustling, male heroin user. The book treats this transformation as a kind of historical forgetting, not proof that medically caused dependence had ceased to be possible.

OxyContin and the return of expansive prescribing

The introduction of OxyContin in 1996 brought the question back into ordinary medical practice. Purdue Pharma promoted the drug for chronic pain beyond cancer and presented addiction risk as very low. David Haddox, the company’s pain specialist and public advocate for the drug, told physicians that taking opioids as prescribed carried a risk of addiction of less than one percent. Company training likewise characterized doctor-caused addiction as exceptionally rare. The message made broad prescribing appear compatible with safety and responsible care.

This promotion met a changing medical environment. Doctors, hospitals, and accreditation bodies were adopting pain as the fifth vital sign, placing it alongside blood pressure, heart rate, respiratory rate, and temperature. In 1999, the Joint Commission approved mandatory standards for pain assessment and treatment. At the same time, patients were increasingly treated as health-care consumers whose experiences were formally rated; patient-satisfaction measures and competition for reimbursement encouraged clinicians to address pain more assertively.

Purdue recognized the commercial opening in these standards. Its budget plan described the opportunity to become a leader in helping hospitals meet the new requirements through pain-assessment and pain-management materials. The company planned hundreds of thousands of dollars in branded items, including scroll pens, resource binders, and wall charts and clipboards promoting pain as the fifth vital sign. The combination mattered: a medical imperative to take pain seriously could also become a channel for a company selling an opioid.

The unresolved issue was what counted as adequate pain relief. Pain is not directly visible, and the assessment tools made subjective reports appear standardized and objective. A pain scale could assign the same score to very different experiences, depending on the individual’s tolerance; the book notes that reliance on such scales did not correspond to better patient outcomes and was associated with increased opioid prescribing and abuse. John Burton, an emergency-medicine leader at Carilion Clinic, later recalled that physicians had been urged to prioritize pain and that he had wrongly believed a short course of opioid pills could not lead a patient to become dependent. His recollection gives the larger shift a clinical scale: the new confidence was not confined to corporate sales claims.

Supply, place, and economic conditions

The book connects iatrogenic addiction to the expansion of opioid supply rather than treating it as a matter of individual prescribing decisions alone. In the early 1990s, heroin was still concentrated in large cities such as New York, Chicago, and Detroit. Widespread OxyContin prescribing for noncancer pain changed that geography: a doctor in a small town could now supply opioids to patients with back problems and other common conditions. Historian David Courtwright argues that this supply expansion preceded and enabled the broader epidemic; when prescription pills became too costly or difficult to obtain, illicit sellers could meet demand from people dependent on opioids and afraid of withdrawal.

The commercial setting reinforced that change. After the U.S. Food and Drug Administration relaxed rules allowing detailed television advertising for nonnarcotic drugs, pharmaceutical advertising rose from $360 million in 1995 to $1.3 billion in 1998, while companies increasingly used gifts and other methods to reach doctors. Purdue’s representatives concentrated on physicians already prescribing competing painkillers and promoted OxyContin for noncancer conditions. These developments made the medicine’s reach a product of both clinical norms and deliberate sales strategy.

The account also sets opioid supply against economic distress. In rural counties affected by globalization, automation, and the decline of coal, Martinsville and surrounding Henry County saw unemployment exceed 20 percent, food-stamp claims more than triple, and disability rates rise by 60.4 percent. Shannon Monnat describes the collapse of work as kindling and opiates as the spark. That framing does not reduce addiction to economic conditions, or make economic hardship a sufficient explanation; it shows how the availability of powerful painkillers met communities already coping with diminished work and rising disability.

Stigma, treatment, and the continuing pattern

The label iatrogenic distinguishes addiction that begins in medical care from a story of personal vice, but the book shows how quickly shame can again silence families. When reporting on heroin in the suburbs of Roanoke, Virginia, began in 2012, many families were unwilling to speak publicly because they were ashamed. In that year, parents also lacked the online groups that later helped families in different parts of the state exchange information and support. The secrecy surrounding addiction left families to navigate the problem largely on their own.

The divide between health care and criminal justice sharpened that isolation. At a Families Anonymous meeting, two mothers of opioid-addicted young men met; their encounter exposed the gaps between the institutions expected to respond to the epidemic. The book describes addicted people trying to survive and avoid withdrawal while families and volunteers worked to keep them alive. It also notes that commercial actors could profit from those gaps. In this setting, the distinction between medical dependence and illicit drug use did not guarantee a smooth route into treatment.

Stigma extended to medication-assisted treatment. Tess had attended twelve-step meetings but felt judged for taking buprenorphine, which some participants considered incompatible with being clean. Although Narcotics Anonymous officially accepted medication-assisted treatment, members asked to sponsor or mentor her declined. The episode shows how a treatment rooted in medical care could itself be marked as suspect, reproducing a boundary between approved recovery and disapproved drug use.

The same social silence appeared in public institutions. Janine Underwood told a school board and county officials about what was happening in her community and hoped to secure support for prevention work; she later described the response as silence. The book’s history of iatrogenic opioid addiction therefore reaches beyond the origin of a patient’s dependence. It traces how medical authority and commercial promotion can expand exposure, how shifting public images can conceal the role of treatment, and how shame and institutional divisions can obstruct a response even after the consequences become visible.